Goelzer Investment Management Inc. Takes $6.99 Million Position in MBX Biosciences, Inc. $MBX

Goelzer Investment Management Inc. acquired a new position in MBX Biosciences, Inc. (NASDAQ:MBX) during the fourth quarter, Holdings Channel reports. The firm acquired 221,672 shares of the company’s stock, valued at approximately $6,992,000.

Several other institutional investors have also modified their holdings of the company. Russell Investments Group Ltd. grew its holdings in MBX Biosciences by 4,131.4% during the third quarter. Russell Investments Group Ltd. now owns 1,481 shares of the company’s stock worth $26,000 after acquiring an additional 1,446 shares during the period. FNY Investment Advisers LLC acquired a new stake in MBX Biosciences in the 3rd quarter valued at about $27,000. BNP Paribas Financial Markets boosted its position in shares of MBX Biosciences by 117.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,896 shares of the company’s stock valued at $51,000 after purchasing an additional 1,567 shares in the last quarter. SG Americas Securities LLC bought a new position in shares of MBX Biosciences during the 4th quarter valued at about $150,000. Finally, China Universal Asset Management Co. Ltd. acquired a new position in shares of MBX Biosciences in the 3rd quarter worth approximately $88,000.

Insider Activity

In other news, CEO P. Kent Hawryluk purchased 18,500 shares of MBX Biosciences stock in a transaction that occurred on Friday, March 13th. The stock was acquired at an average price of $28.41 per share, for a total transaction of $525,585.00. Following the transaction, the chief executive officer owned 486,777 shares in the company, valued at $13,829,334.57. The trade was a 3.95% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at this link. 52.19% of the stock is owned by corporate insiders.

MBX Biosciences Trading Up 0.7%

NASDAQ MBX opened at $28.50 on Friday. The stock’s 50-day moving average price is $34.31 and its two-hundred day moving average price is $27.67. The company has a market cap of $1.35 billion, a PE ratio of -11.83 and a beta of 1.06. MBX Biosciences, Inc. has a 1 year low of $4.81 and a 1 year high of $44.89.

MBX Biosciences (NASDAQ:MBX) last announced its earnings results on Thursday, March 12th. The company reported ($0.49) EPS for the quarter, topping the consensus estimate of ($0.64) by $0.15.

Analysts Set New Price Targets

A number of analysts recently commented on MBX shares. Guggenheim boosted their target price on shares of MBX Biosciences from $77.00 to $88.00 and gave the stock a “buy” rating in a report on Friday, January 16th. UBS Group restated a “buy” rating on shares of MBX Biosciences in a report on Tuesday, February 24th. Barclays began coverage on shares of MBX Biosciences in a research report on Tuesday, January 27th. They issued an “overweight” rating and a $66.00 price target on the stock. Stifel Nicolaus upped their price target on MBX Biosciences from $45.00 to $50.00 and gave the company a “buy” rating in a report on Friday, December 19th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of MBX Biosciences in a research note on Thursday, January 22nd. Ten investment analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $51.56.

MBX Biosciences Company Profile

We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEPTM, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients.